Cargando…

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

INTRODUCTION: Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD. METHODS: This phase 2, multicenter, randomized, double-blind, placebo-controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tyring, Stephen K., Rich, Phoebe, Tada, Yayoi, Beeck, Stefan, Messina, Izabella, Liu, Jie, Huang, Xiaohong, Shumack, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805909/ https://www.ncbi.nlm.nih.gov/pubmed/36588137 http://dx.doi.org/10.1007/s13555-022-00876-x

Ejemplares similares

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial
por: Kimball, Alexa B., et al.
Publicado: (2023)

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study
por: Zhao, Y., et al.
Publicado: (2021)

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
por: Kamata, Masahiro, et al.
Publicado: (2021)

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
por: Kamata, Masahiro, et al.
Publicado: (2023)

Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial
por: Yang, Hyeon-Jong, et al.
Publicado: (2014)

Effects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial
por: Hsiao, Yun-Hsia, et al.
Publicado: (2016)

Efficacy of Probiotics in Children and Adolescents With Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
por: de Andrade, Paula Danielle Santa Maria Albuquerque, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
por: Papp, Kim A., et al.
Publicado: (2021)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
por: Bissonnette, R., et al.
Publicado: (2019)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Hwangryunhaedoktang in adult patients with Atopic Dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial - study protocol
por: Kim, Nam-Kwen, et al.
Publicado: (2011)

KM110329 in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, multicentre trial – study protocol
por: Cheon, Chunhoo, et al.
Publicado: (2013)

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
por: Silverberg, J.I., et al.
Publicado: (2021)

Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report
por: TAKEOKA, Shintaro, et al.
Publicado: (2021)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

Effect of Evening Primrose Oil on Korean Patients With Mild Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Study
por: Chung, Bo Young, et al.
Publicado: (2018)

A multi-center, double-blind, randomized, placebo- and positive-controlled phase II clinical study of benvitimod for the treatment of atopic dermatitis
por: Cai, Lin, et al.
Publicado: (2023)

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
por: Wollenberg, A., et al.
Publicado: (2020)

Risankizumab for psoriasis
Publicado: (2020)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial
por: Warren, R.B., et al.
Publicado: (2020)

Efficacy of Pseudo-Ceramide-Containing Steroid Lamellar Cream in Patients with Mild to Moderate Atopic Dermatitis: A Randomized, Double-Blind Study
por: Okoshi, Keita, et al.
Publicado: (2022)

Efficacy and Safety of Socheongryong-Tang Among Atopic Dermatitis Patients With Respiratory Disorders: A Double-Blinded, Randomized, Placebo-Controlled Clinical Trial
por: Lee, Ju Hyun, et al.
Publicado: (2020)

Randomized, double-blind, placebo-controlled clinical trial measuring the effect of a dietetic food on dermatologic scoring and pruritus in dogs with atopic dermatitis
por: de Santiago, Miguel Sánchez, et al.
Publicado: (2021)

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
por: Baeten, Dominique, et al.
Publicado: (2018)

Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Efficacy and safety of Soshiho-tang in patients with atopic dermatitis and gastrointestinal disorders: Study protocol for a double-blind, randomized, and placebo-controlled clinical trial
por: Kang, Su-Jin, et al.
Publicado: (2019)

The efficacy and safety of Longmu Tang granule for the treatment of atopic dermatitis: study protocol for a single-centred, double-blinded, randomised, placebo-controlled trial
por: Li, Ya-qin, et al.
Publicado: (2022)

Efficacy and safety of So-Cheong-Ryong-Tang in patients with atopic dermatitis and respiratory disorders: Study protocol of a double-blind randomized placebo-controlled trial
por: Kang, Su-Jin, et al.
Publicado: (2020)

Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
por: Abe, Tatsuya, et al.
Publicado: (2022)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ftfbk5m04re6q2m2grh5v0v3dh